Overview

Gender

male

Eric Dobmeier joined Seattle Genetics in March 2002 and has served as our Chief Operating Officer since June 2011. He manages the company's business development, legal, corporate communications, process sciences, technical operations and project management groups. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the ex-U.S./Canada development and commercialization agreement with Takeda Pharmaceutical Company for brentuximab vedotin and ten ADC collaborations with leading biotechnology and pharmaceutical companies.He has also participated in raising more than $600 million in equity financing for Seattle Genetics. Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman LLP where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions.
Mr. Dobmeier serves as a director of Stemline Therapeutics, Inc. He received a J.D. from University of California, Berkeley School of Law and an A.B. in History from Princeton University.